Scottish Medicines Consortium lacosamide (Vimpat)

Scottish Medicines Consortium lacosamide (Vimpat)

in the absence of a submission from the holder of the marketing authorisation:

lacosamide (Vimpat®) is not recommended for use within NHS Scotland.

Indication under review: As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Name: lacosamide (Vimpat)
SMC Drug ID: 1324/18
Manufacturer: UCB Pharma Ltd
Indication: As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 March 2018

To read more Press Release articles, click here.